Meeting
2019 Gastrointestinal Cancers Symposium
Updated results of the BEACON CRC safety lead-in: Encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mCRC).
Authors
Scott Kopetz
University of Texas MD Anderson Cancer Center, Houston, TX
Scott Kopetz , Axel Grothey , Rona Yaeger , Pieter-Jan AR Cuyle , Sanne Huijberts , Jan H. M. Schellens , Elena Elez , Marwan Fakih , Clara Montagut Viladot , Marc Peeters , Jayesh Desai , Takayuki Yoshino , Fortunato Ciardiello , Harpreet Singh Wasan , Kati Maharry , Janna Christy-Bittel , Ashwin Gollerkeri , Eric Van Cutsem , Josep Tabernero
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT02928224
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 688)
DOI
10.1200/JCO.2019.37.4_suppl.688
Abstract #
688
Poster Bd #
N13
Abstract Disclosures
Similar Posters
![BEACON CRC (binimetinib [BINI], encorafenib [ENCO], and cetuximab [CTX] combined to treat BRAF-mutant metastatic colorectal cancer [mCRC]): A multicenter, randomized, open-label, three-arm phase III study of ENCO plus CTX plus or minus BINI vs irinotecan (IRI)/CTX or infusional 5-fluorouracil/folinic acid/IRI (FOLFIRI)/CTX with a safety lead-in of ENCO + BINI + CTX in patients (Pts) with BRAF<sup>V600E</sup> mCRC.](https://d201v5jt9ylckg.cloudfront.net/199/11943/153243/153243_poster_pv.jpg)
First Author: Sanne Huijberts
Poster
2023 ASCO Gastrointestinal Cancers Symposium
BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy for BRAFV600E metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2018 Gastrointestinal Cancers Symposium
BEACON CRC study safety lead-in (SLI) in patients with BRAFV600E metastatic colorectal cancer (mCRC): Efficacy and tumor markers.
First Author: Eric Van Cutsem
Poster
2023 ASCO Gastrointestinal Cancers Symposium
TRIDENTE trial: A phase II study of rechallenge with encorafenib, binimetinib, and cetuximab in patients with RAS wild-type/BRAF V600E–mutant metastatic colorectal cancer.
First Author: Daisuke Kotani